Skip to main content
Top
Published in: Osteoporosis International 2/2006

01-02-2006 | Original Article

Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women

Authors: J. Lundkvist, O. Johnell, C. Cooper, D. Sykes

Published in: Osteoporosis International | Issue 2/2006

Login to get access

Abstract

Parathyroid hormone (PTH) is a new treatment for osteoporosis and has been shown to reduce the risks of vertebral and non-vertebral fractures in postmenopausal women in clinical trials. The objective of this study was to estimate the cost-effectiveness of teriparatide in addition to calcium and vitamin D, using a simulation model. The base case analysis was conducted for a cohort of 69-year-old women in Sweden who had at least one previous vertebral fracture and low bone mineral density. The model simulated the course of events in 6-month cycles in individual patients until death or 100 years of age. During each cycle the patients were at risk of experiencing clinical vertebral, hip or wrist fractures, or death. Total accumulated life-time costs and quality-adjusted life years (QALYs) were estimated. Swedish data on fracture costs, utility reductions after fracture, fracture risks and mortality rates were used. The model incorporated new epidemiological evidence that indicates fracture risks and mortality rates are higher in the subsequent years post-fracture. The results showed that the cost-effectiveness of the treatment is highly dependant on the risk profile of the treated patients and the timing of starting treatment relative to previous fractures. The cost per QALY gained for treatment of a population of 69-year-olds with a T-score at the femoral neck of −3 was in the base case estimated to be between EUR (€) 20,000 and 64,000 for patients with a recent or historic vertebral fracture respectively. The study provides further evidence of the benefit and cost-effectiveness of starting osteoporotic treatments early in patients with a new fracture, and also that teriparatide may provide valuable clinical benefits for these patients and may be considered a cost-effective intervention when targeted to the appropriate patients.
Literature
1.
go back to reference Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795 Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795
2.
go back to reference Melton LJ 3rd (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 14 [Suppl 1]:S1–8 Melton LJ 3rd (1993) Hip fractures: a worldwide problem today and tomorrow. Bone 14 [Suppl 1]:S1–8
3.
go back to reference Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124 Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118–4124
4.
go back to reference McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340 McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340
5.
go back to reference Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535 Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528–4535
6.
go back to reference Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441.
7.
go back to reference Lindsay R, Scheele W, Clancy A, Mitlak B (2001) Incident vertebral fractures during an 18-month observation period following discontinuation of ly333334 [recombinant human parathyroid hormone (1–34), rhPTH (1–34] use in postmenopausal women with osteoporosis. J Bone Min Res 16 [Suppl 1]:S163 Lindsay R, Scheele W, Clancy A, Mitlak B (2001) Incident vertebral fractures during an 18-month observation period following discontinuation of ly333334 [recombinant human parathyroid hormone (1–34), rhPTH (1–34] use in postmenopausal women with osteoporosis. J Bone Min Res 16 [Suppl 1]:S163
8.
go back to reference Lindsay R, Scheele W, Clancy A, Mitlak B (2001) Maintenance of reduction in nonvertebral fragility fractures 18 months after discontinuation of recombinant human parathyroid hormode (1–34) use in postmenopausal women with osteoporosis. Osteoprosos Int 12 [Suppl 2]:S46 Lindsay R, Scheele W, Clancy A, Mitlak B (2001) Maintenance of reduction in nonvertebral fragility fractures 18 months after discontinuation of recombinant human parathyroid hormode (1–34) use in postmenopausal women with osteoporosis. Osteoprosos Int 12 [Suppl 2]:S46
9.
go back to reference Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18–23 Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18–23
10.
go back to reference Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179 Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175–179
11.
go back to reference Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42 Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38–42
12.
go back to reference Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S, Gathon HJ, Haim M, et al (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841–857 Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S, Gathon HJ, Haim M, et al (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841–857
13.
go back to reference Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314 Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314
14.
go back to reference Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136–142 Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136–142
15.
go back to reference Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365 Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365
16.
go back to reference Zethraeus N, Jönsson B, Lindgren P (2000) A computer model to analyze the cost-effectiveness of hormone replacement therapy—a revised version. Stockholm: Economic Research Insitute (EFI) Zethraeus N, Jönsson B, Lindgren P (2000) A computer model to analyze the cost-effectiveness of hormone replacement therapy—a revised version. Stockholm: Economic Research Insitute (EFI)
17.
go back to reference Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11:669–674 Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11:669–674
18.
go back to reference Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259 Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259
19.
go back to reference Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585–590 Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585–590
20.
go back to reference Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821–828 Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821–828
21.
go back to reference Kanis J, Brazier J, Stevenson M, Calvert N, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment, NHS R&D HTA program 6 (29) Kanis J, Brazier J, Stevenson M, Calvert N, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment, NHS R&D HTA program 6 (29)
22.
go back to reference Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120–127 Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120–127
23.
go back to reference (2003) Statistics Sweden. Sweden’s Statistical Databases (2003) Statistics Sweden. Sweden’s Statistical Databases
24.
go back to reference Browner WS, Pressman AR, Nevitt MC, Cummings SR (1996) Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 156:1521–1525 Browner WS, Pressman AR, Nevitt MC, Cummings SR (1996) Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 156:1521–1525
25.
go back to reference Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473 Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473
26.
go back to reference Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68:13–17 Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68:13–17
27.
go back to reference Zethraeus N (2002) Costs and quality of life associated with osteoporosis related fractures—based on a Swedish pilot study. Stockholm: Centre for Health Economics (Stockholm School of Economics) Zethraeus N (2002) Costs and quality of life associated with osteoporosis related fractures—based on a Swedish pilot study. Stockholm: Centre for Health Economics (Stockholm School of Economics)
28.
go back to reference Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38 Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38
29.
go back to reference (2000) Stadsledningenskontorets redovisningsstab. The municpality of Stockholm. Stockholm: Stockholms stads budgetavräkning (2000) Stadsledningenskontorets redovisningsstab. The municpality of Stockholm. Stockholm: Stockholms stads budgetavräkning
30.
go back to reference De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10:66–72 De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10:66–72
31.
go back to reference LINFO (2003) FASS Läkemedel i Sverige (Swedish drug prices). Oslo, Läkemedelsinformation AB LINFO (2003) FASS Läkemedel i Sverige (Swedish drug prices). Oslo, Läkemedelsinformation AB
32.
go back to reference Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16:33–64 Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16:33–64
33.
go back to reference Ekman M, Zethraeus N, Dahlstrom U, Hoglund C (2002) [Cost-effectiveness of bisoprolol in chronic heart failure]. Lakartidningen 99:646–650 Ekman M, Zethraeus N, Dahlstrom U, Hoglund C (2002) [Cost-effectiveness of bisoprolol in chronic heart failure]. Lakartidningen 99:646–650
34.
go back to reference Lundberg L (1999) Health-related quality of life in Sweden. Dissertation. Faculty of Pharmacy, Uppsala University, Uppsala Lundberg L (1999) Health-related quality of life in Sweden. Dissertation. Faculty of Pharmacy, Uppsala University, Uppsala
35.
go back to reference Hall SE, Criddle RA, Comito TL, Prince RL (1999) A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 9:508–515 Hall SE, Criddle RA, Comito TL, Prince RL (1999) A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 9:508–515
36.
go back to reference Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042–1049 Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042–1049
37.
go back to reference Ekman M, Johnell O, Lidgren L (2004) The economic cost of low back pain in Sweden. Forthcoming in Spine Ekman M, Johnell O, Lidgren L (2004) The economic cost of low back pain in Sweden. Forthcoming in Spine
38.
go back to reference Ekman M, Jönhagen S, Hunsche E, Jönsson L (2004) Burden of illnesss of chronic low back pain in Sweden: a cross-sectional, retrospective study in primary care setting. Forthcoming in Acta Orthopaed Scand Ekman M, Jönhagen S, Hunsche E, Jönsson L (2004) Burden of illnesss of chronic low back pain in Sweden: a cross-sectional, retrospective study in primary care setting. Forthcoming in Acta Orthopaed Scand
39.
go back to reference Atlas SJ, Nardin RA (2003) Evaluation and treatment of low back pain: an evidence-based approach to clinical care. Muscle Nerve 27:265–284 Atlas SJ, Nardin RA (2003) Evaluation and treatment of low back pain: an evidence-based approach to clinical care. Muscle Nerve 27:265–284
40.
go back to reference Hollingworth W, Deyo RA, Sullivan SD, Emerson SS, Gray DT, Jarvik JG (2002) The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Econ 11:71–85 Hollingworth W, Deyo RA, Sullivan SD, Emerson SS, Gray DT, Jarvik JG (2002) The practicality and validity of directly elicited and SF-36 derived health state preferences in patients with low back pain. Health Econ 11:71–85
41.
go back to reference Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427 Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427
42.
go back to reference Lothgren M, Zethraeus N (2000) Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9:623–630 Lothgren M, Zethraeus N (2000) Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9:623–630
43.
go back to reference Melton LJ, 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383–388 Melton LJ, 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383–388
44.
go back to reference Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251–258 Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251–258
45.
go back to reference Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 6:9–17 Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 6:9–17
46.
go back to reference Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7:518–528 Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7:518–528
47.
go back to reference Ekman M (2002) Studies in health economics: EFI, Stockholm School of Economics, Stockholm Ekman M (2002) Studies in health economics: EFI, Stockholm School of Economics, Stockholm
Metadata
Title
Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women
Authors
J. Lundkvist
O. Johnell
C. Cooper
D. Sykes
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 2/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-005-1959-4

Other articles of this Issue 2/2006

Osteoporosis International 2/2006 Go to the issue